This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268–74.
Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.
Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res. 2019;31:15–9.
Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG, et al. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie’s disease. Urology. 2017;100:125–30.
Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–9.
Kuhlmann PK, DeLay KJ, Anaissie J, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives. Patient Prefer Adherence. 2017;11:431–48.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
LAL is a speaker and consultant for Boston Scientific and Coloplast. PT declares that he has no conflicts of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tsambarlis, P., Levine, L.A. Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res 32, 257–258 (2020). https://doi.org/10.1038/s41443-019-0180-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-019-0180-5